Any views on the impairment reversals of $47m in the 2023 year and $35m in the 2022 year and equate to a significant part of earnings.
Obviously these benefit EBIT, which I note is what management is assessed on for STI, predominantly, and feeds into improved EPS.
- Forums
- ASX - By Stock
- MRM
- Looks seriously undervalued still
Looks seriously undervalued still, page-16
-
- There are more pages in this discussion • 18 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)